After 11 years of development and barely one full year of sales, New York–based Pfizer dumped the much-anticipated inhaled powder insulin product Exubera on 18 October. This was particularly bad ...

Armed with new data, GSK is preparing to file for approval of its new-generation meningitis vaccine, as it tries to maintain its leadership in the category against a challenge from Pfizer.